Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GL0034 PK in Renal Impairment
NCT07385547Phase 1Recruiting
- Sponsor
- Sun Pharma
- Start
- Feb 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of utreglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Sun Pharma. Primary endpoints: Maximum concentration, Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
utreglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07385547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07385547.